Find Clinical Trials

On this page, you will find different kinds of study results:

• A Lay summary which is a summary of clinical trial results written in an easy-to-understand way.
• A summary of results called synopsis which is written in scientific language. It is prepared for Medicines Agencies and Ethics Committees,
• A scientific publication which presents results for scientists and medical doctors.

219 Results

Protocol Code	Study Title	Active substance/Medical device	Study Phase	Therapeutic Area
CL3-16257-068	Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo…	IVABRADINE, S016257	Phase 3	Cardiovascular Diseases
CL3-16257-067	Long-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at…	IVABRADINE, S016257	Phase 3	Cardiovascular Diseases
CL3-16257-064	Evaluation of the anti-anginal efficacy and safety of ivabradine used in combination with an anti-anginal…	IVABRADINE, S016257	Phase 3	Cardiovascular Diseases
CL3-16257-063	Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure…	IVABRADINE, S016257	Phase 3	Cardiovascular Diseases
CL3-16257-057	Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo…	IVABRADINE, S016257	Phase 3	Cardiovascular Diseases
CL3-16257-056	Effects of ivabradine on cardiovascular events in patients with stable coronary artery disease and left…	IVABRADINE, S016257	Phase 3	Cardiovascular Diseases
CL3-12911-040	Knee joint replacement over 5 years in patients with knee osteoarthritis. A long term follow…	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-12911-038	A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration…	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-12911-037	A prospective, controlled, double blind, international study to assess the effects of strontium ranelate vs.…	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-12911-036	Effect of strontium ranelate (2g per day) in the management of long bone fractures with…	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-12911-035	A multicenter, prospective, randomized, double-blind, placebo-controlled, international study to assess the effects of 2g per…	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-12911-032	The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis. A…	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-12911-030	A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of…	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-12911-028	Long-term effects of strontium ranelate on knee osteoarthritis symptoms. A 2-year prospective, randomised, placebo-controlled study.	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-12911-025	A double-blind, multicenter, international randomised study to assess the effects of 6 months or 12…	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-12911-022	The efficacy and safety of two doses of strontium ranelate versus placebo administered orally for…	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-12911-019	A double-blind, multicentric, multinational randomised study to assess the effects of one year administration of…	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-12911-018	The efficacy and safety of two doses of strontium ranelate (1g and 2g per day)…	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-12911-016	The efficacy and safety of 2g strontium ranelate in the treatment of osteoporosis in men.…	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-12911-012	SOTI and TROPOS phase III studies open-label extension. The long term efficacy and long term…	STRONTIUM RANELATE, S012911	Phase 3	Rheumatology
CL3-09490-144	Effects of perindopril on mortality/morbidity in patients with stable coronary artery disease without clinical heart…	PERINDOPRIL TERT BUTYLAMINE, S009490	Phase 3	Cardiovascular Diseases
CL3-06911-003	The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3…	STRONTIUM RANELATE, VITAMINE D, S006911	Phase 3	Rheumatology
CL3-06911-002	The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3…	STRONTIUM RANELATE, VITAMINE D, S006911	Phase 3	Rheumatology
CL3-06795-008	Clinical acceptability of trimetazidine 80 mg once daily compared to trimetazidine 35 mg twice daily…	TRIMETAZIDINE, S006795	Phase 3	Cardiovascular Diseases
CL3-06790-010	The efficacy and safety of trimetazidine in patients with angina pectoris having been treated by…	TRIMETAZIDINE, S006790	Phase 3	Cardiovascular Diseases

Previous 1 2 … 4 5 6 … 8 9 Next